New schizophrenia drug shows promise in phase 2 trial
NCT ID NCT06179108
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 31 times
Summary
This study tested a new medicine called LB-102 in 359 adults with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and confusion better than a placebo over 28 days. Researchers measured changes using standard symptom scales and also checked safety and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Behavioral Clinical Research, Inc.
Hollywood, Florida, 33021, United States
-
CelExel CNS
Garden Grove, California, 92845, United States
-
CelExel Clinical Innovations
Bellflower, California, 90706, United States
-
CenExel ACMR
Atlanta, Georgia, 30331, United States
-
CenExel CBH
Gaithersburg, Maryland, 20877, United States
-
CenExel CIT Riverside
Riverside, California, 92506, United States
-
CenExel HRI
Berlin, New Jersey, 08009, United States
-
CenExel RCA
Hollywood, Florida, 33024, United States
-
CenExel iResearch
Decatur, Georgia, 30030, United States
-
Community Clinical Research
Austin, Texas, 78754, United States
-
InSite Clinical Research
DeSoto, Texas, 75115, United States
-
Midwest Clinical Research Center
Dayton, Ohio, 45417, United States
-
NRC Research Institute
Santa Ana, California, 92705, United States
-
Neuro-Behavioral Clinical Research
North Canton, Ohio, 44720, United States
-
Pillar Clinical Research
Bentonville, Arkansas, 72712, United States
-
Pillar Clinical Research
Chicago, Illinois, 60641, United States
-
Pillar Clinical Research
Richardson, Texas, 75080, United States
-
ProScience Research Group
Culver City, California, 90230, United States
-
Richmond Behavioral Associates
Staten Island, New York, 10314, United States
-
Segal Institute for Clinical Research
Miami Lakes, Florida, 33016, United States
-
Synergy Research
Lemon Grove, California, 91945, United States
-
Synexus
Cerritos, California, 90703, United States
-
Uptown Research Institute
Chicago, Illinois, 60640, United States
-
Woodland Internation Research Group
Little Rock, Arkansas, 72211, United States
-
Woodland Research Northwest
Rogers, Arkansas, 72758, United States
Conditions
Explore the condition pages connected to this study.